We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Feasibility and Safety of Oral Nutritional Supplementation with High-Density Liquid Diet After Total Gastrectomy for Gastric Cancer.
- Authors
Yamada, Takanobu; Hayashi, Tsutomu; Fujikawa, Hirohito; Kumazu, Yuta; Nagasawa, Shinsuke; Nakazono, Masato; Kano, Kazuki; Hara, Kentaro; Watanabe, Hayato; Komori, Keisuke; Shimoda, Yota; Takahashi, Kosuke; Ogata, Takashi; Oshima, Takashi; Yoshikawa, Takaki
- Abstract
Introduction: Patients requiring total gastrectomy for gastric cancer experience a decrease in food intake leading to severe body weight loss after surgery. This loss may be prevented using a high-density liquid diet of high caloric content and minimal volume. This phase II study evaluated the feasibility and safety of a high-density liquid diet (UpLead®; Terumo Corporation, Tokyo, Japan) after total gastrectomy. Methods: UpLead® (1 pack, 100 mL, 400 kcal/day) was administered after surgery for 28 days. The primary endpoint was the % relative dose intensity of 28 days of UpLead intake®. The secondary endpoint was % body weight loss at 1 and 3 months after surgery. The sample size was 35 considering expected and threshold values of 80 and 60%, respectively, with a one-sided alpha error of 10% and statistical power of 80%. Results: Among 35 patients enrolled before surgery between April 2018 and December 2019, 29 patients who could initiate UpLead® after surgery were analyzed. Seven patients had interrupted UpLead® intake due to taste intolerance (n = 6) and due to a duodenal stump fistula (n = 1). The remaining 22 patients completed 28 days of UpLead® intake, including temporary interruption, with no associated adverse events. The median relative dose intensity was 25.8% (95% confidence interval: 20.6–42.0%). The median body weight loss at 1 and 3 months after surgery was 7.2% (range: 3.2–13.9%) and 13.1% (range: 2.5–20.4%), respectively. Conclusions: Oral nutritional supplementation with a high-density liquid diet (UpLead®) was safely administered but was not feasible after total gastrectomy for gastric cancer. Clinical trial registration number UMIN000032291.
- Subjects
DIETARY supplements; STOMACH cancer; BARIATRIC surgery; GASTRECTOMY; WEIGHT loss
- Publication
World Journal of Surgery, 2022, Vol 46, Issue 10, p2433
- ISSN
0364-2313
- Publication type
Article
- DOI
10.1007/s00268-022-06639-1